pharma · Relapsing-Remitting Multiple Sclerosis · Spinal Muscular Atrophy
Biogen
NovaPharmaNews editorial coverage mentioning Biogen — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- 225 Binney Street, Cambridge, MA 02142, US
- Employees
- 7,534
- Programs
- 31
- Drugs
- 45
- Patents
- 25
News & analysis
NovaPharmaNews articles mentioning Biogen — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Biogen — regulatory, clinical, and market analysis.
Biogen and Eisai expand Leqembi access with subcutaneous maintenance dosing
Biogen and Eisai have expanded LEQEMBI access in the U.S. with subcutaneous maintenance dosing, following FDA approval of the BLA in August 2025. The move could improve convenience, reduce infusion-related burden, and shape investor expectations for Eisai and Biogen stock.
Eisai's Leqembi Sales Forecast: Projecting Blockbuster Status in Alzheimer's
Eisai projects significant growth for its Alzheimer's treatment, Leqembi, with sales forecasts indicating a strong path toward blockbuster status. This analysis explores the drivers behind this projection and its strategic implications for the pharmaceutical industry.
Biogen's Alzheimer's Data and Leadership Shake-up: Implications for Pharma BD
Biogen faces scrutiny following recent Alzheimer's data releases and executive departures. This analysis explores the implications for pharmaceutical business development and investment strategies.
Biogen Faces Italian Antitrust Probe: What It Means for the Multiple Sclerosis Market
Biogen's Italian subsidiary and its US parent are under investigation by the Italian antitrust authority for alleged abuse of a dominant position in the multiple sclerosis market. This probe, stemming from concerns over drug pricing and market practices, could have significant repercussions for Biogen and the broader MS therapeutic area.
Biogen Under Investigation: Implications for the Pharma Industry
Biogen faces scrutiny from the Italian regulator regarding market abuse claims related to multiple sclerosis. This article explores the implications for the pharmaceutical industry.
Biogen and Denali's Parkinson's Drug Trial: What Went Wrong?
Biogen and Denali's recent trial for a Parkinson's drug has not met expectations, raising questions about future strategies and investments in this space.
Biogen and Denali Abandon Parkinson's Drug After Study Setback
Biogen and Denali have decided to discontinue their drug for non-genetic Parkinson's disease following disappointing mid-stage study results. This article explores the implications for the pharmaceutical landscape.